Overview
Sweden biopharma research tools firm's Q1 sales rose 4%, or 17% currency-adjusted
Q1 EPS rose to SEK 0.06 from SEK 0.05, with improved EBITDA margin
Result Drivers
CURRENCY HEADWINDS - Strengthening Swedish krona reduced reported sales growth by about SEK 4 mln, despite strong underlying performance
PHARMA CUSTOMER GROWTH - Organic growth among large pharmaceutical companies exceeded 30% in the quarter
LOWER SERVICE REVENUE - Service revenue was significantly lower due to absence of large project orders seen in Q1 2025
Company press release: ID:nMFN5YtgwG
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Slight Beat*
SEK 33.51 mln
SEK 33.50 mln (2 Analysts)
Q1 EPS
SEK 0.06
Q1 EBITDA
SEK 9.51 mln
Q1 Operating Cash Flow
SEK 16.51 mln
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Genovis AB is SEK31.00, about 54.6% above its April 27 closing price of SEK20.05
The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 33 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
